Stocks · News reference
XORTX Therapeutics Starts Production Of Drug, Tablet Manufacturing For Its XRx-026 Trial To Treat Gout
XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why
XORTX Therapeutics shares climb 22.16% after hours as company advances plans for a Canadian gout drug trial.
XORTX Therapeutics Plans Health Canada Clinical Trial Application For Gout Drug XORLO Ahead Of Planned FDA Filing
XORTX Therapeutics shares are trading higher after the company outlined its anticipated IND application submission to the FDA for the XRx-026 gout program.